+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-01-29Number of Pages: 100

Inhalation and Nasal Spray Generic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Inhalation and Nasal Spray Generic Drugs Market: Snapshot

The growing number of generic drugs in the market today is primarily attributed to the patent expirations in various medical fields, including inhalers and nasal sprays. The absence of the need for research and development or major marketing strategies allows the average price of generic drugs to have been US$35.22 in 2008, as opposed to the US$137.9 average for branded drugs, according to the NACDS.

The sales of generic inhalers and nasal sprays is expected to increase even further after the release of studies that point to an increase in the number of patients suffering from restrictive and even life-threatening respiratory diseases, such as COPD and asthma. The incredibly high healthcare costs, especially in developed economies, is therefore driving this growing patient pool towards generic drugs.

Quality control could pose an issue in the overall growth of generic inhalers and nasal spray sales, an issue that governments are trying to control through increasing the stringency of related regulatory frameworks and quality assurance measures.

After reviewing the above facts along with many others in detail, it is deduced that the global market for inhalation and nasal spray generic drugs market is expected to be valued nearly US$24.5 bn by the end of 2016. In 2023, this market is expected to reach US$35.4 bn in revenue. It is therefore expected to display a CAGR of 5.5% from 2015 to 2023.

Asia Pacific Population Holds High Promise of Growth for Generic Inhalers and Nasal Spray Manufacturers

The two largest regional consumers of generic inhalers and nasal sprays in 2014 were North America and Europe. By the end of 2016, their market revenues are expected to reach close to US$8.8 bn and US$5 bn respectively. In comparison, the market in Asia Pacific is expected to be valued at US$4.3 bn by the end of 2016. Although it is currently the third-largest regional consumer of generic inhalers and nasal sprays, it is the fastest-growing one.

North America and Europe are dominating the production and consumption of generic inhalation and nasal spray drugs due to the high level of patient safety and care protocols maintained here through the imposition of very strict government regulations. On the other hand, Asia Pacific holds a rapidly evolving healthcare industry, coupled with the highest population density in the world. These factors, along with the increasing patient pool for COPD and asthma, is expected to make players focus more on Asia Pacific.

A majority of generic inhalation and nasal spray drugs consumption will go to China and Japan, Australia and India are showing high promise due to their governments showing the intent of reducing overall healthcare costs.

Combination Inhalers and Nasal Sprays Will Continue to Dominate Sales and Revenue till 2023

The major drug classes of generic inhalation and nasal spray drugs include corticosteroids, bronchodilators, antihistamines, combinations, and decongestant sprays. Of these, the top CAGR of 5.9% between 2015 and 2023 will be held by combination sprays. These sprays remain one of the most preferred medical solutions to asthma and COPD in most countries. Studies have also proved the higher effectiveness of combination sprays and inhalers for the treatment of severe respiratory diseases.

The key manufacturers of inhalation and nasal spray generic drugs include Mylan N.V., Allergan plc, Nephron Pharmaceuticals Corporation, and Cipla Ltd.

This report on the inhalation and nasal spray generic drugs market studies the current and future prospects of the global market. Growing incidences of respiratory diseases such as asthma and COPD, increasing geriatric population, and increasing number of generic manufacturers is expected to accentuate the growth of inhalation and nasal spray generic drugs market globally. The inhalation and nasal spray generic drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global inhalation and nasal spray generic drugs market with respect to market segments based on drug class, medical indication and their geographic analysis. 

Based on drug class, the inhalation and nasal spray generic drugs market has been segmented into five major categories: corticosteroids, bronchodilators, antihistamines, combinations, and decongestant sprays. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year. 

Geographically, the global inhalation and nasal spray generic drugs market has been categorized into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World. The market size and forecast for each of these regions has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions. A detailed qualitative analysis of factors responsible for driving and restraining the growth of the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis by drug class and geography, as well as market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global inhalation and nasal spray generic drugs market. 

Current and future trends has also been provided for new entrants as well as existing market players to assist them in taking strategic initiatives to establish a strong presence in the market. The report also profiles major players in the inhalation and nasal spray generic drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Allergan plc, Mylan N.V., Ranbaxy Laboraotries Ltd., Roxane Laboratories, Inc., Beximco Pharmaceuticals Ltd., Cipla Ltd., and Nephron Pharmaceuticals Corporation.

The global inhalation and nasal spray generic drugs market is segmented as given below:

Global Inhalation and Nasal Spray Generic Drugs Market, by Drug Class, 2013-2023 (US$ Mn)

  • Corticosteroids
    • Fluticasone
    • Budesonide
    • Beclomethasone
    • Flunisolide
    • Others (mometasone, ciclesonide etc.)
  • Bronchodilators
    • Albuterol
    • Epinephrine
    • Others
  • Antihistamines
  • Combinations
    • Salmeterol/Fluticasone
    • Formoterol/Budesonide
    • Azelastine/Benzalkonium Chloride
    • Others
  • Decongestant Sprays
    • Phenylephrine hydrochloride
    • Oxymetazoline hydrochloride

Global Inhalation and Nasal Spray Generic Drugs Market, by Drug Class, 2013-2023 (US$ Mn)

  • Asthma
  • COPD
  • Allergic Rhinitis
  • Other Respiratory Disorders

Global Inhalation and Nasal Spray Generic Drugs Market, by Geography, 2013 – 2023 (US$ Mn)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and North Africa
    • Saudi Arabia
    • Egypt
    • United Arab Emirates
    • Rest of MENA
  • Rest of the World (RoW)


 
 
Back To Top